30 closest matches · ranked by relevance
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 83.7; 62.0 percentage of participants
Leukemia · Myeloproliferative Disorders · Myelodysplastic-Myeloproliferative Diseases
Primary: Two-year Overall Survival — 46; 51 percentage of patients
Diamond-Blackfan Anemia · Kostmann's Neutropenia · Shwachman-Diamond Syndrome
Primary: Number of Patients Alive (Survival) at 2 Years — 6 Participants
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
Hematologic Malignancies · Bone Marrow Transplant Rejection
Primary: The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30 — 44.9 percentage of participants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
Sickle Cell Disease
Primary: Percentage of Participants With Overall Survival (OS) at 2 Years After Biologic Assignment — 89; 94 percentage of participants
Hematologic Diseases · Hematologic Malignancies
Primary: Numbers of Participants With Disease-free Survival. — 10 participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Percentage of Participants Who Develop Acute Graft-versus-host Disease (GVHD) — 49; 10 Participants
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 73.5; 54.0 percentage of participants
Sickle Cell Disease
Primary: Percentage of Participants With Two-Year Post-Transplant Event Free Survival (EFS) — 88.0; 79.3 Percentage of Participants
B-Cell Prolymphocytic Leukemia · Hypodiploidy · Loss of Chromosome 17p
Primary: Event-Free Survival (EFS) — 9 Participants
Sickle Cell Disease
Primary: Event -Free Survival Rate — 19 Participants
Primary Immunodeficiency · PID
Primary: Safety: Death — 4 Participants
Sickle Cell Disease
Primary: Percentage of Participants With Event-Free Survival (EFS) — 76; 69 percentage of participants
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia · Burkitt's Lymphoma
Primary: Percentage of Participants With Progression Free Survival (PFS) — 35.0; 41.1 percentage of participants — p=0.4092
Hematologic Malignancies
Primary: Overall Survival of Participants — 13 participants
Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Primary: Overall Survival (OS) in Patients With Haploidentical Family Donors With Hematological Malignancies in Morphological or Radiographic Remission or With Chemosensitive…
MDS · Leukemias · Lymphomas
Primary: Engraftment as Measured by Donor Chimerism — 91 percentage of participants
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Donor Engraftment (Chimerism) — 34 Participants
Systemic Scleroderma · Severe Systemic Sclerosis
Primary: Event-free Survival (EFS) — 1 Participants
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
Leukemia · Myelodysplastic Syndromes
Primary: Overall Survival at 5 Years Post-Transplant. — 40 percentage of survival probability
Inherited Immune Deficiencies
Primary: Stem Cell Transplant Engraftment — 7; 31; 3; 0 Participants
Mucopolysaccharidosis · Hurler Syndrome · Hunter Syndrome
Primary: Number of Patients With Donor Derived Engraftment — 42 Participants
Acute Myeloid Leukemia · Myelodysplastic Syndromes · Biphenotypic Leukemia
Primary: Disease-Free Survival (DFS) — 78.6 percentage of patients
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912) — 22; 39; 43 percentage of participants